Acquisitions

Novartis AbbVie Sanofi Bristol Myers Squibb Corporate Finance Competition Private Equity Biopharma Icosavax Acquisition Icosavax First Wave BioPharma Inc AstraZeneca PLC Clinical Trials Genmab AstraZeneca Vertex Pharmaceuticals Cancer Treatment Drug Development Cancer Treatments Zydus Lifesciences Organon & Co COVID-19 Impact

5 ARTICLES

last wk.

Merck Announces €3 Billion Acquisition of Springworks Therapeutics

The deal aims to bolster Merck's rare tumor treatments, accelerate growth, and expand its U.S. presence, pending regulatory and shareholder approvals.

4 ARTICLES

2w ago

AbbVie Acquires Neuroscience Biotech Cerevel for $8.7 Billion

Particle.news

Acquisitions

Merck Announces €3 Billion Acquisition of Springworks Therapeutics

Merck in Advanced Talks to Acquire Springworks Therapeutics for $3.5 Billion

Sanofi Secures $1.9 Billion Deal for Dren Bio’s Innovative Autoimmune Therapy

French Government Intervenes in Doliprane Ownership Amid Worker Strikes

Pfizer Faces Activist Pressure as Ex-Execs Withdraw Support for Starboard

Organon Acquires Dermavant from Roivant for Up to $1.2 Billion

Genmab Acquires ProfoundBio for $1.8 Billion to Expand Cancer Treatment Options

Novo Nordisk Acquires Cardior Pharmaceuticals for $1.1 Billion

AstraZeneca Acquires Amolyt Pharma for $1.05 Billion

Novartis Acquires MorphoSys for $2.9 Billion, Expanding Cancer Drug Portfolio

Bristol Myers Squibb Acquires RayzeBio for $4.1 Billion

Bristol Myers Squibb Acquires Karuna Therapeutics in $14 Billion Deal

AstraZeneca to Acquire Icosavax for $1.1 Billion

AbbVie Acquires Cerevel Therapeutics for $8.7 Billion

AbbVie Acquires Neuroscience Biotech Cerevel for $8.7 Billion

Never miss stories about

Acquisitions